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Abstract
Background: Mucopolysaccharidosis-IVA (Morquio A disease) is a lysosomal disorder in which the abnormal
accumulation of keratan sulfate and chondroitin-6-sulfate is consequent to mutations in the galactosamine-
6-sulfatase (GALNS) gene. Since standard DNA sequencing analysis fails to detect about 16% of GALNS
mutant alleles, gross DNA rearrangement screening and uniparental disomy evaluation are required to
complete the molecular diagnosis. Despite this, the second pathogenic GALNS allele generally remains
unidentified in ~ 5% of Morquio-A disease patients.
Methods: In an attempt to bridge the residual gap between clinical and molecular diagnosis, we
performed an mRNA-based evaluation of three Morquio-A disease patients in whom the second mutant
GALNS allele had not been identified. We also performed sequence analysis of the entire GALNS gene in
two patients.
Results: Different aberrant GALNS mRNA transcripts were characterized in each patient. Analysis of these
transcripts then allowed the identification, in one patient, of a disease-causing deep intronic GALNS
mutation. The aberrant mRNA products identified in the other two individuals resulted in partial exon loss.
Despite sequencing the entire GALNS gene region in these patients, the identity of a single underlying
pathological lesion could not be unequivocally determined. We postulate that a combination of multiple
variants, acting in cis, may synergise in terms of their impact on the splicing machinery.
Conclusions: We have identified GALNS variants located within deep intronic regions that have the
potential to impact splicing. These findings have prompted us to incorporate mRNA analysis into our
diagnostic flow procedure for the molecular analysis of Morquio A disease.
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Background
Mucopolysaccharidosis IV-A or Morquio A disease
(MIM #253000] is an autosomal recessive lysosomal
storage disease caused by the deficiency of N-acetyl-
galactosamine-6-sulfatase (GALNS), the lysosomal en-
zyme responsible for the hydrolytic degradation of
keratan sulfate and chondroitin-6-sulfate [1]. GALNS
is encoded by the GALNS gene (NM_000512.4) which
is located on chromosome 16q24.3; the gene has a
length of about 50 kb and is organized into 14 exons
[2]. The GALNS gene is alternatively spliced, with two
other reported protein coding transcripts in the RefSeq
database (NM_001323543.1 and NM_001323544.1) [3]. In
Ensembl, 13 transcripts are reported of which four are
protein coding [4].
In excess of 330 different mutations have been reported
in the GALNS gene causing Morquio A disease (Human
Gene Mutation Database; http://www.hgmd.org). Among
them, only one solitary deep intronic mutation which cre-
ated a cryptic donor splice site was previously reported [5].
Empirically, standard sequencing procedures, covering all
GALNS exons and intron/exon boundaries, have failed to
identify ~ 16% of mutant alleles in patients affected by the
disease [6, 7]. However, this percentage falls to 5% when
gross DNA rearrangements are also screened for [8].
Morquio A disease affects multiple organ systems but
its principal features are the cartilage defects, caused by
keratan sulfate accumulation, that are responsible for the
typical skeletal complications including coxa valga, scoli-
osis, short trunk dwarfism and cervical instability [1, 9].
The diagnosis tends to be particularly challenging in at-
tenuated Morquio A patients, with consequent increased
risk for missing the correct diagnosis [1].
Several therapeutic approaches including hematopoietic
stem cell transplantation, gene therapy, substrate reduc-
tion therapy, and enzyme replacement therapy (ERT) have
been developed in order to try to ameliorate the disease
[10–14].
Newborn screening, whether by tandem mass spec-
trometry on dried blood spots and/or by fluorimetric as-
says, has proved to be both reliable and effective in
identifying most mucopolysaccharidoses, including Mor-
quio A disease [15, 16]. It is likely that the widespread
adoption of this methodology will have a significant im-
pact on the diagnosis of Morquio A disease [9, 17, 18].
Here we delineate the criteria that we have found
efficacious in making an early diagnosis of Morquio
A disease, together with a novel screening strategy
that we have devised in order to optimize the prob-
ability of obtaining a molecular diagnosis in each
case. Adoption of this strategy allowed the identifica-
tion of novel splicing defects in three individuals in
whom only one GALNS coding region mutation had
originally been found.
Methods
Patients
The clinical features, and biochemical [urinary excretion
of glycosaminoglycans (GAGs) and GALNS enzyme ac-
tivity] and molecular analyses of these three Morquio A
disease patients are summarized in Table 1. None of
these patients has been previously reported. Based upon
various empirical measurements to establish the severity
of the MPS IVA phenotype [i.e. age at onset, growth/
height (based on gender) and life span; [9, 19]], Pt1 and
Pt3 are affected by the severe form of the disease,
whereas Pt2 may be defined as mild.
The patients’ parents gave their written consent for
genetic testing to be performed on a local consent form,
in accordance with the Declaration of Helsinki.
Biochemical assays
Total urinary glycosaminoglycans (GAGs) were assayed as
previously described [20]. Qualitative GAGs assay was per-
formed by thin layer chromatography [21]. GALNS enzyme
activity was measured from leukocytes/lymphocytes
employing the fluorogenic method [22]. Beta-galactosidase
(GLB1) activity was assayed in all patient samples as previ-
ously reported [23, 24] in order to allow exclusion of Mor-
quio B syndrome.
It should be noted that control values for total
urinary GAG evaluation can differ quite markedly be-
tween samples when the assays are performed in dif-
ferent centres, even though all such centres are
qualified to perform the diagnostic assays. Urine kera-
tan sulfate was found to be abundant in all samples
from the three analysed patients.
T-lymphocyte cell culture and treatment with
cycloheximide to rescue aberrant transcripts from
nonsense-mediated mRNA decay (NMD)
Patient and control T-lymphocytes were cultured in
RPMI medium supplemented with fetal bovine serum
(heat inactivated for 30 mins at 56 °C), interleukin 2
(800 U/ml), phytohemagglutinin (2.5 μg/ml) and antibi-
otics. The pool of control T-lymphocytes was separated
from blood derived from 10 normal individuals. For
each patient and control, lymphocytes were treated
with (or without) 100 mg/ml cycloheximide (Sigma-Al-
drich, Saint Louis, Missouri, USA) for 16 h. Total
mRNA extraction and RT-PCR analysis are described
below. Cycloheximide is used to identify cases of abnor-
mal mRNA processing caused by mutations that gener-
ate premature termination codons (PTCs) that are then
subject to NMD [25–27]. PTCs can result either from
nonsense or frameshift mutations or from errors that
occur during transcription or mRNA splicing [28]. Cy-
cloheximide, being a translation elongation inhibitor,
acts as a potent NMD inhibitor [26].
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Analysis of GALNS genomic DNA, total mRNA and cDNA
synthesis
Genomic DNA was isolated from the patients’ peripheral
blood lymphocytes. GALNS exons were PCR amplified
using oligonucleotides and reaction conditions reported
previously [8].
Isolation of total mRNA from cultured lymphocytes (with
and without the addition of cycloheximide) was performed
with the RNeasy Mini Kit (Qiagen, Hilden, Germany) for
cells and tissues and the QIAamp RNA Blood Mini kit
(Qiagen, Hilden, Germany) for blood samples. RNA con-
centrations were determined with a Nanodrop® ND-1000
Spectrophotometer (Nanodrop technologies, Wilmington,
USA). RNA integrity was checked on a 1% agarose gel.
GALNS mRNA reverse transcription was carried out as
previously described [29]. Nucleotide numbering of the
GALNS gene corresponded to the GenBank reference se-
quence, NM_000512.4. Patient mutational homozygosity
and/or parental carrier status were verified by targeted
DNA sequence analysis of the GALNS gene in each pa-
tient’s parents.
Quantitative fluorescent PCR (QF-PCR) analysis and copy
number variation (CNV) assays
QF-PCR fragments corresponding to all GALNS exons
were obtained both by simplex and multiplex amplifica-
tions on genomic DNAs. CNV assays were performed
combining TaqMan® MGB probe chemistry with Real
Time PCR instruments (Applied Biosystems® 7500
Real-Time PCR) (Life Technologies Italia, Monza, Italy).
The methods employed were as previously described [8].
Whole GALNS gene sequencing and filtering of genetic
variants
DNA samples from patients Pt2 and Pt3 were prepared
using the TruSeq DNA PCR-Free protocol (Illumina Inc.,
Table 1 Clinical biochemical and molecular features of MPSIVA patients
Patient 1 2 3
Phenotype severe mild severe
Age 14 y 6 m 16y 14y
Age at diagnosis 3y 5 m 8y 3y
Age at onset 3 m 3y 2-3y
GALNS activity (nmol/17 h/mg
protein)
0.07 (nv 40–170) 0.2 (nv 40–170) 0 (nv 70–180)
Genotype c.463G > A (ex 5)/ c.899-167A > G c.463 G > A (ex 5)/ c.1002 +
307G > C^
c.697G > A (ex 7)/ c.759-
67G > A^
mRNA alteration −/ r.898_899ins53 −/ r.1003_1119del −/ r.456_916del
Protein alteration p.Gly155Arg / p.Gly300Valfs*37 p.Gly155Arg/
p.(Val335_Leu373del)
p.Asp233Asn/
p.(Lys153_Phe306del)
Sex female female male
Parental consanguinity no no no
Height (cm) at diagnosis 89.5 121 –
Height (cm) at last observation 108.6 136.3 114.5
Weight (kg) 18.2 26.6 27.5
Spondyloepiphyseal dysplasia yes yes yes
Chest deformity yes yes yes
Hearing loss – no yes
Corneal clouding no mild no
Coxa valga yes yes yes
Odontoid hypoplasia yes yes no
Hepatomegaly no yes mild
Cardiomyopathy yes no no
Valvular regurgitation – no mitral/ tricuspid
Mental retardation no no WISC-III TIQ 89
Surgery (type and age) odontoid hypoplasia (7y), coxa valga (13y),
cardiomyopathy (9 m)
right hip (6y), left hip (7y), coxa
valga (10y)
coxa valga (10y)
Urine GAGs (mg/g creatinine) 92 (nv 48–82) 52 (nv 10–63) 6.6 (nv 2.1–23.2)
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San Diego, CA, USA) and sequenced with an Illumina
HiSeqX Ten generating 150 bp paired-end reads. All frag-
ments were mapped to the hg19 human genome reference
sequence using iSAAC align version 03.16.12.05. Genetic
variants identified within the GALNS gene region
(NM_000512.4, chr16:88880141–88,923,374) in both pa-
tients (Pt2; 144 variants and Pt3; 73 variants) were filtered
in an attempt to identify the variant(s) ultimately respon-
sible for the observed splicing defects. The first filter was
employed to eliminate variants called with low confidence
(< 20 Phred quality score). A second filter was then applied
to remove those variants which had been found to occur
with a minor allele frequency of > 1% in the 1000 Genomes
Project data (http://www.internationalgenome.org/). A
location-based filter was also applied to remove those vari-
ants that were considered unlikely, based on their location,
to be responsible for the splicing defect (thus, for example,
the partial deletion of exon 10 in the aberrant mRNA
transcript of Pt2 was deemed most unlikely to have
been caused by a variant in exon 1). Therefore, for
Pt2, this location-based filter was applied to the range
chr16:88898406–88,891,277 (hg19), starting at the first
base of GALNS IVS9 and extending to the last base
of IVS10 (NM_000512.4). With patient Pt3, the loca-
tion filter was applied to the range chr16: 88907400–
88,893,246 (hg19) spanning the first base of GALNS
IVS4 to the last base of IVS9 [the aberrant mRNA
splicing phenotype in Pt3 involved the skipping of
half of exon 5, all of exons 6, 7 and 8, plus half of
exon 9]. Manual review of the remaining variants
employed Human Splicing Finder 3.0 (HSF; http://
www.umd.be/HSF3/) to assess the potential impact of
these variants on the mRNA splicing phenotype. Zygosity
in the patients’ parents was also employed to filter out
likely non-pathogenic GALNS variants e.g. those variants
found in the homozygous state in a clinically unaffected
parent. The Combined Annotation-Dependent Depletion
(CADD) method [30] was also used under manual review
to rank the variants in terms of their potential pathogen-
icity; the higher the CADD score, the higher the probabil-
ity that the variant is disease-causing.
Results
GALNS gene and mRNA molecular analyses
In our cohort of about 40 Morquio A patients [8, 29,
31], the second disease-causing mutation remained
uncharacterized in only three patients; the genetic
analysis of these patients is reported here. Although
heterozygous GALNS mutations were identified in all
three patients (1, 2 and 3), the second anticipated
pathogenic GALNS variant was not found in any of
them by standard sequencing procedures. As depicted
in the flowchart (Fig. 1), the presence of large dele-
tions/duplications was excluded by means of
quantitative fluorescent-PCR and copy number vari-
ation analysis as previously described [8].
GALNS gene and mRNA molecular analyses in Pt1
Initial GALNS gene sequencing analysis of Pt1 revealed a
paternally inherited heterozygous c.463G >A (p.Gly155Arg)
mutation, previously described as being disease-causing
[32], but no evidence of a maternally inherited lesion.
GALNS mRNA analysis, performed by RT-PCR on
lymphocytes from Pt1, revealed two distinct RT-PCR
products, one corresponding to the wild-type GALNS
transcript, the other slightly larger. The normal RT-PCR
product harboured the c.463G > A (p.Gly155Arg) muta-
tion whereas the aberrant RT-PCR product contained a
53-nucleotide sequence insertion between exons 8 and
9. When this inserted sequence was aligned to the
GALNS gene sequence, it was identified as DNA se-
quence originating from intron 8, which had been in-
cluded as a consequence of the activation of a cryptic
donor splice site. Hence, the added DNA sequence con-
stitutes, in effect, a cryptic exon (Fig. 2f ).
The targeted sequencing of GALNS intron 8 from Pt1
then revealed the mRNA defect to be due to a novel het-
erozygous c.899–167 A > G transition that serves to cre-
ate an additional donor splice site (Human Splicing
Finder; http://www.umd.be/HSF3/). The upstream splice
acceptor site that was co-activated, thereby allowing in-
clusion of the 53 bp cryptic exon, was an AG dinucleo-
tide flanked by a stretch of pyrimidines on its 5′ side
(Additional file 1: Figure S3). The sequence of the aber-
rant GALNS mRNA transcript predicted a frameshift
ending in a premature stop codon located at position
c.953 within exon 9 (Gly300Valfs*37) (Fig. 2f; Additional
file 1: Figure S3). The c.899–167 A > G lesion was also
detected in the heterozygous state in the mother of Pt1.
The GALNS gene and mRNA molecular analyses in Pt2
and Pt3
Standard sequencing of the GALNS gene identified a sin-
gle missense mutation in both Pt2 and Pt3 [p.Gly155Arg
and p.Asp233Asn, respectively], but failed to identify the
second disease-causing mutation in either patient. Further,
RT-PCR analysis of the GALNS gene initially failed to re-
veal any additional RT-PCR products in Pt2 and Pt3 as
compared to normal controls (data not shown). However,
the same analysis performed on T-lymphocytes grown in
the presence of cycloheximide revealed the presence of
aberrant RT-PCR products in both patients (Fig. 2a-e).
The aberrant in-frame RT-PCR product detected in
Pt2 would predict the omission of 117 nt from exon 10
of the GALNS transcript [r.1003_1119del, p.(Val335_-
Leu373del)] (Fig. 2e). The aberrant splicing product de-
tected in lymphocyte cDNA samples from Pt3 was
sequenced and shown to have resulted from the
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skipping of half of exon 5, all of exons 6, 7 and 8, plus
half of exon 9 (r.456_916del; Fig. 2a) thereby generating
a frameshift.
The GALNS mRNA evaluation performed in the father
of Pt2 identified the same deletion, r.1003_1119del, that
had been detected in the proband. By contrast, RT-PCR
analysis revealed that the r.456_916del lesion detected in
Pt3 was absent from his parents whilst two aberrant
transcripts, characterized by different (albeit similar) de-
leted portions of GALNS exons, were detected in the
mother of Pt3 (Fig. 2b and c). In addition, in both Pt3
and his father, an aberrant GALNS splicing product, that
harboured the deletion of exon 9, was identified
(Fig. 2d). In silico analysis suggested that both the
c.697G >A (p.Asp233Asn) and c.775C > A (p.Arg259Arg)
nucleotide changes could alter splicing (see HSF
Fig. 2 Aberrant splicing products detected in Morquio A patients in the heterozygous state. The alternative GALNS cDNA (RT-PCR) products were
detected in samples from: a Pt3; b, c Mother of Pt3; d Pt3 and his father; e Pt2; f Pt1. Ten normal controls were included alongside the three
patients in the mRNA analyses in order to compare the GALNS cDNA amplification products. The control group did not show any aberrant
transcripts. Del, deletion; ins, insertion; trunc, truncated; ex, exon
Fig. 1 Diagnostic flowchart for Morquio A disease. The flowchart illustrates our clinical/laboratory analytical procedure. It should be noted that
the procedure includes mRNA analysis in addition to DNA and protein analysis
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predictions given in Table 2); c.697G >A (p.Asp233Asn)
in Pt3 corresponds to the pathological lesion harboured
by the paternal GALNS allele. Since c.775C >A
(p.Arg259Arg) was found in cis with the c.697G >A
(p.Asp233Asn) mutation in Pt3 (i.e. it also has a paternal
origin), it cannot correspond to the second pathological
lesion anticipated in the GALNS gene of Pt3, despite its
potential impact on splicing (Table 2). The c.697G >A
(p.Asp233Asn) and c.775C >A (p.Arg259Arg) substitu-
tions were nevertheless both identified, apparently in the
homozygous state, in the aberrant splicing product
lacking exon 9 that was detected in both Pt3 and his
father (Fig. 2d), thereby confirming their likely role in
generating this aberrant splicing product.
Whole GALNS gene sequence analysis
Among the list of GALNS gene variants identified in
genomic DNA samples from Pt2 and Pt3 [143 variants
in Pt2 and 69 variants in Pt3, data not shown], in silico
analyses identified several potentially pathogenic variants
(summarised in Table 2).
The c.1002 + 307G >C variant detected in Pt2 was pre-
dicted to result in mis-splicing (Table 2) and represents a
highly plausible candidate pathological lesion (i) on the
basis of its location within intron 9, (ii) because the mu-
tant allele creates an exonic splicing enhancer (ESE) site
and (iii) because it is predicted to create an exon-identity
element (ccgcct) [33] and may possibly also create or abol-
ish splice silencer motifs [34].
The c.759-67G > A variant, identified in both patient
Pt3 and his mother, represents the most plausible candi-
date for the observed splicing defect in these individuals.
Although it should be appreciated that the consequences
for mRNA splicing of changes in exonic splicing regula-
tory elements are often unpredictable, this deep intronic
variant (c.759-67G > A) is predicted to abolish an exist-
ing exonic splicing silencer (ESS) motif while creating a
novel ESE motif.
Intriguingly, the observed RNA splicing phenotypes dif-
fered between patient Pt3 and his mother. Thus, whereas
the GALNS mRNA transcript in Pt3 harboured a 461 bp
deletion (Fig. 2a), his mother exhibited two quite distinct
mis-spliced transcripts, the first harbouring a 521 bp dele-
tion, the second an indel comprising a 385 bp deletion to-
gether with a 21 bp insertion (Fig. 2b-c).
Discussion
The spectrum of pathological mutations and benign poly-
morphisms in the GALNS gene displays considerable allelic
heterogeneity [HGMD Professional (Stenson et al., 2017),
Exome Variant Server (http://evs.gs.washington.edu/EVS/),
GALNS Mutation Database (http://galns.mutdb.org/data-
base) etc.]. However, in approximately 16% of patients, the
anticipated second disease-causing GALNS mutation can-
not be unequivocally identified within the gene coding re-
gion or at the exon-intron boundaries [6, 7].
Establishing a diagnostic plan, including the requisite gen-
etic analyses, is essential to distinguish between bona fide
Morquio A disease patients and individuals with other dis-
orders presenting with similar clinical and radiological find-
ings [6, 9, 12]. In addition, early diagnosis is crucial for the
prompt deployment of available therapies before permanent
systemic lesions occur. Here, we have integrated a series of
clinical and analytical tools to provide a diagnostic flow
chart for Morquio A disease (Fig. 1). In the algorithm we
propose, next generation sequencing (NGS) procedures
Table 2 GALNS nucleotide sequence variants with potential significance in the generation of the GALNS aberrant splicing products
detected in Pt2 and Pt3
Chr: Pos
(GRCh37.p13)
Zygosity Parental
Zygosity
Variant Type Identifier (dbSNP
149, NCBI)
Exon/
Intron
MAF HSF Summary/CADD score
Pt2
16:88898099 Heterozygous Paternal
(heterozygous)
c.1002 +
307G > C
rs866140272 INTRON
9
– ESE gain and alterations to various ESRs -
CADD 3.002
Pt3
16:88901744 Heterozygous Paternal
(heterozygous)
c.775C > A;
p.Arg259Arg
rs61742258 EXON 8 0.002 Cryptic donor splice site created, ESE loss
and ESS gain - CADD 14.49
16:88901827 Heterozygous Maternal
(heterozygous)
c.759-67G > A rs565875595 INTRON
7
0.001 ESE gain and ESS loss - CADD 6.652
16:88902194 Heterozygous Paternal
(heterozygous)
c.697G > A;
p.Asp233Asn
rs753051547 EXON 7 – Alteration of an exonic ESE site - CADD 24.1
16:88905035 Heterozygous Maternal
(heterozygous)
c.423-862C > T – INTRON
4
– Cryptic donor splice site created - CADD
0.094
- = not present in gnomAD browser beta (http://gnomad.broadinstitute.org/); MAF =minor allele frequency; ESE = exonic splicing enhancer; ESS = exonic splicing
silencer; ESRs = exonic splicing regulatory sequences; HSF (Human Splicing Finder) predictions = a tool which assesses the potential impact of these variants on
the mRNA splicing phenotype (http://www.umd.be/HSF3/); CADD = Combined Annotation Dependent Depletion = a tool for scoring the deleteriousness of single
nucleotide variants as well as insertion/deletion variants in the human genome. A CADD score of > 10 is applied as a threshold to identify high-confidence
disease-causing mutations [27]
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may be employed in two distinct analytical steps (Fig. 1). In
the first, the exonic sequences and exon-intron boundaries
of the gene in question are sequenced by NGS methodology
(whole exome); alternatively, whole genome sequencing can
be employed to sequence the entire gene region (~ 50 kb).
In a second step, high-throughput sequencing-based
methods can be used to perform transcriptome analysis
(RNA-Seq) [35], including of course, in our case, GALNS
transcripts.
We have presented here the cases of three Morquio A
patients in whom the second disease-causing GALNS
mutation was not initially identifiable either by standard
sequencing procedures or by the analysis of gross DNA
rearrangements and instead had to be determined by
means of RT-PCR. Aberrant GALNS mRNA splicing
products were noted in all three patients. In Pt1, the
deep intronic mutation c.899–167 A > G was unequivo-
cally identified as the lesion responsible for the aberrant
mRNA (including an elongated exon) and a prematurely
truncated GALNS protein. Hence, this aberrant splicing
event can be directly and unambiguously related to the
severe clinical phenotype observed in this patient.
Mutations located within deep intronic regions, that ap-
pear capable of promoting the use of alternative natural or
non-natural splicing sites, were identified by GALNS
whole gene sequencing analyses of Pt2 and Pt3 samples.
After following the variant prioritisation protocol de-
scribed above, specific GALNS variants in Pt2 (c.1002 +
307G >C) and Pt3 (c.759-67G >A) were predicted to
make a contribution to the clinical phenotype in these in-
dividuals by impacting mRNA splicing. These variants ex-
hibited a very low Minor allele frequency (MAF), and
were predicted to modulate splicing, particularly with re-
spect to potential ESE and ESS sequences.
Since both of the aberrantly spliced products de-
tected in Pt2 and Pt3 disrupt exons, the mechanism
responsible for these splicing alterations cannot be
precisely ascertained. Indeed, it remains possible that
a particular combination of variants could have been
responsible for the observed splicing defects, rather
than one variant on its own. Consequently, it may be
that any of the other variants detected in the patients,
including the putatively non-pathogenic GALNS vari-
ants (143 variants in Pt2 and 69 variants in Pt3,
post-prioritization), may have contributed to the gen-
eration of the non-physiological splicing events de-
tected e.g. c.423-862C > T identified in Pt3 and his
mother. It should also be appreciated that variants
such as c.423-862C > T may disrupt canonical splice
junction sequences, i.e. cryptic acceptor and donor
splice sites. Thus, it may well be that it is the com-
bination of altered canonical and non-canonical splice
sites in both patients that gives rise to these unique
splicing alterations.
The GALNS gene is known to be alternatively spliced,
with at least three known protein coding transcripts cur-
rently annotated (NM_00512.4, NM_001323544.1 and
NM_00132354.1). It is possible that these alternative
transcripts were differentially expressed between Pt3 and
his mother; if so, this might have led to changes in spli-
cing factor supply and demand, which could in turn ac-
count for the differences in the observed mRNA splicing
phenotype between the patient and his mother.
Owing to the difficulties inherent in interpreting this
atypical type of splicing event and our veritable ignor-
ance of splicing regulatory regions, our approach did
not unequivocally identify disease-causing variants at
the DNA level for Pt2 and Pt3 even after intensive
DNA sequence analysis of the GALNS gene region.
Additional functional studies, including the construc-
tion of expression systems that variously combine the
identified candidate mis-spliced variants, would be ne-
cessary to formally confirm our hypotheses. However,
for diagnostic purposes, the pathogenicity of the ob-
served mRNA splicing defects is evidenced by: a) the
absence of RT-PCR amplification, corresponding to the
aberrant mRNA transcripts detected in Pt2 and Pt3
samples, in a pool of 10 normal controls both treated
and untreated with cycloheximide; b) the splicing prod-
ucts detected in Pt2 and Pt3 differing from the 13
known GALNS physiological mRNAs, collected in the
Ensembl Human Genome browser (http://www.ensem-
bl.org/index.html). These considerations imply that the
alternative GALNS mRNA splicing products detected in
Pt2 and Pt3 are non-physiological, and are therefore
likely to be consequent to the (hitherto unidentified)
second disease-causing GALNS alleles in these Morquio
A patients.
Conclusions
Morquio A disease is particularly prone to delayed
diagnoses and/or misdiagnoses, owing to the difficul-
ties inherent in the differential diagnosis of this
rheumatic disease that requires specialist metabolic
expertise. The addition of mRNA analysis and whole
GALNS gene sequencing to this flowchart promises
to help to identify those molecular causes of Mor-
quio A disease which until now have been refractory
to analysis. These analyses are likely to be particu-
larly important for Morquio A screening programs
in which the drawing up of a general diagnostic mo-
lecular plan is key to distinguishing between new-
borns who are carrying mutations associated with
severe forms of the disease and those who are carry-
ing mutations that are likely to give rise to milder or
asymptomatic forms.
Our sequence analysis of the GALNS gene, involv-
ing gene level, genomic and RT-PCR analyses,
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suggests that although deep intronic mutations may
be individually infrequent, they may be largely re-
sponsible for our occasional failure to identify GALNS
disease alleles in Morquio A disease; it follows that
marked improvements in our knowledge of the spli-
cing machinery will be required before any diagnostic
workflow can be regarded as being 100% effective.
Additional file
Additional file 1 Figure S3. Sequence analysis of the aberrant mRNA
transcript generated as a consequence of the c.899–167 A > G lesion
identified in the GALNS gene of Pt1. A. GALNS mRNA sequence and
schematic representation of the wild-type splicing event. B. Aberrant mRNA
splicing resulting from the intronic c.899–167 A > G transition. (PPT 425 kb)
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